文献速递浆细胞疾病造血干细胞移植与细胞治疗

CASSIOPEIA研究:D-VTd与VTd方案在适合移植新诊断多发性骨髓瘤患者中的健康相关生活质量结局

Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2020-01-01

CASSIOPEIA是一项随机、开放标签、3期试验,纳入适合移植的新诊断多发性骨髓瘤患者,随机接受D-VTd或VTd方案。预设二次分析显示,两组从基线到诱导后及巩固后全球健康状况评分变化无显著差异,但D-VTd组在巩固后疼痛减轻更显著、认知功能恶化更少、情绪功能改善更明显。

要点

  • D-VTd与VTd均改善患者治疗期间健康相关生活质量。
  • D-VTd组巩固后疼痛减轻显著优于VTd组。
  • D-VTd组认知功能下降更少且情绪功能改善更明显。

核心结论

  • D-VTd和VTd均与适合移植新诊断多发性骨髓瘤患者治疗期间健康相关生活质量改善相关。
  • D-VTd较VTd在疼痛减轻、认知功能保护和情绪功能改善方面更优,支持在标准方案中加入达雷妥尤单抗。

研究设计与样本

  • CASSIOPEIA为正在进行的随机、开放标签、活性对照、平行组3期试验,在欧洲111个学术和社区中心开展。
  • 适合移植的新诊断多发性骨髓瘤成人患者按1:1随机分配至D-VTd组(n=543)或VTd组(n=542)。
  • 治疗包括自体造血干细胞移植前4个28天周期的诱导治疗和移植后2个28天周期的巩固治疗。
  • 预设二次分析纳入意向治疗人群中具有基线和至少一次基线后患者报告结局评估的患者。
  • 患者报告结局采用EORTC QLQ-C30和EQ-5D-5L问卷在基线、诱导后(第4周期第28天)和巩固后(自体造血干细胞移植后第100天)评估。

主要发现

  • 基线问卷完成率高:D-VTd组511/543(94%),VTd组510/542(94%)。
  • 诱导后问卷依从率高:D-VTd组431/513(84%),VTd组405/509(80%);巩固后:D-VTd组414/460(90%),VTd组386/438(88%)。

临床怎么用

  • 对于适合移植的新诊断多发性骨髓瘤患者,D-VTd方案在生活质量方面具有额外获益,尤其疼痛、认知功能和情绪功能。
  • 临床决策时可综合考虑D-VTd对患者报告结局的改善作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In part 1 of the two-part CASSIOPEIA study, treatment before and after autologous haematopoietic stem-cell transplantation (HSCT) with daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTd) significantly improved rates of stringent complete response and progression-free survival versus bortezomib, thalidomide, and dexamethasone (VTd) in patients with newly diagnosed multiple myeloma. METHODS: CASSIOPEIA is an ongoing randomised, open-label, active-controlled, parallel-group, phase 3 trial done at 111 academic and community practice centres in Europe. Transplantation-eligible adults with newly diagnosed multiple myeloma were randomly assigned (1:1) to D-VTd or VTd. Treatment consisted of four 28-day cycles of induction therapy before autologous HSCT and two 28-day cycles of consolidation therapy after. In this prespecified secondary analysis, patient-reported outcomes were assessed using the European Organization for Research and Treatment of Cancer quality of life questionnaire-core 30-item (EORTC QLQ-C30) and EuroQol 5-dimensional descriptive system (EQ-5D-5L) questionnaire at baseline, after induction (cycle 4, day 28), and after consolidation (day 100 after autologous HSCT). The analysis was done in all patients in the intention-to-treat population with a baseline and at least one post-baseline patient-reported outcome assessment. The trial is registered at ClinicalTrials.gov (NCT02541383). FINDINGS: Between Sept 22, 2015, and Aug 1, 2017, 1085 patients were enrolled and randomly assigned D-VTd (n=543) or VTd (n=542). Questionnaire completion rates were high at baseline (511 [94%] of 543 in the D-VTd group vs 510 [94%] of 542 in the VTd group). Compliance rates (calculated from the number of completed surveys as a proportion of the predicted number of participants still on study treatment) were high at post-induction (431 [84%] of 513 vs 405 [80%] of 509) and post-consolidation (414 [90%] of 460 vs 386 [88%] of 438) assessments and were similar between treatment groups. Mean changes in global health status scores from baseline to post-induction were not different between the D-VTd group (3·8 [95% CI 1·6 to 6·0]) and VTd group (2·9 [0·7 to 5·1]; p=0·43), or from baseline to post-consolidation between the two groups (D-VTd group, 9·7 (95% CI 7·4 to 11·9) vs VTd group, 8·7 (6·5 to 11·0; p=0·45). Improvements from baseline in EORTC QLQ-C30 global health status and EQ-5D-5L visual analogue scale scores were observed in post-consolidation scores in both groups. Post-consolidation scores showed significantly greater mean decreases in pain (-23·3 [95% CI -26·6 to -20·0] in the D-VTd group vs -19·7 [-23·0 to -16·3] in the VTd group; p=0·042), significantly smaller reductions in cognitive functioning (-5·0 [-7·6 to -2·4] vs -7·9 [-10·6 to -5·3]; p=0·036), and significantly greater improvements in emotional functioning (13·0 [10·4 to 15·5] vs 9·5 [6·9 to 12·1]; p=0·013) and in constipation (-3·2 [-7·3 to 0·9] vs 1·8 [-2·4 to 6·0]; p=0·025) with D-VTd versus VTd. Between-group differences in change from baseline for all other scales were not significant. INTERPRETATION: D-VTd and VTd were associated with on-treatment health-related quality of life improvements from baseline in transplantation-eligible patients with newly diagnosed multiple myeloma. The significantly greater reductions in pain, less deterioration of cognitive functioning, and greater emotional functioning improvements complement the clinical benefits observed with D-VTd versus VTd, and support the addition of daratumumab to standard regimens in patients with newly diagnosed multiple myeloma. FUNDING: Intergroupe Francophone du Myélome, The Dutch-Belgian Cooperative Trial Group for Hematology Oncology, and Janssen Research and Development.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Roussel M, Moreau P, Hebraud B, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. Lancet Haematol. 2020. PMID: 33242444. doi:10.1016/S2352-3026(20)30356-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。